**Administration Case Report With EXPAREL**

This case report represents the individual experience of Dr. Stuart E. Lieblich and is intended to demonstrate his methodology for using EXPAREL in a specific oral/maxillofacial procedure.

Pacira Pharmaceuticals, Inc. recognizes that there are alternative methodologies for administering local anesthetics, as well as individual patient considerations when selecting the dose for a specific procedure.

EXPAREL is indicated for administration into the surgical site to produce postsurgical analgesia.

### CASE INFORMATION

<table>
<thead>
<tr>
<th><strong>Physician Name</strong></th>
<th>Stuart E. Lieblich, DMD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Affiliation</strong></td>
<td>Department of Oral and Maxillofacial Surgery, University of Connecticut Avon Oral &amp; Maxillofacial Surgery, Avon, CT</td>
</tr>
<tr>
<td><strong>Surgical Case Performed</strong></td>
<td>Third-molar extractions</td>
</tr>
<tr>
<td><strong>Inpatient or Outpatient Procedure</strong></td>
<td>Outpatient</td>
</tr>
</tbody>
</table>

### PATIENT CHARACTERISTICS

| **Gender** | Female |
| **Age** | 19 years |
| **Patient History and Characteristics** | Recurrent lower-right pericoronitis |
| **Pathology** | Soft tissue impactions of teeth #1 and #16; partial bony impactions of teeth #17 and #32 |

### PROCEDURAL DETAILS

<table>
<thead>
<tr>
<th><strong>Incision Size</strong></th>
<th>2-cm sulcular incisions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Preoperative Analgesics Used</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Upper Molars</strong></td>
<td>• 2% lidocaine with 1:100,000 epinephrine for infiltration into the buccal and palatal aspects</td>
</tr>
<tr>
<td><strong>Lower Molars</strong></td>
<td>• 2% lidocaine with 1:100,000 epinephrine for inferior alveolar nerve block and lingual nerve block in the mandible*</td>
</tr>
<tr>
<td></td>
<td>• 0.5% bupivacaine HCl with 1:100,000 epinephrine for inferior alveolar nerve block and long buccal nerve block*</td>
</tr>
<tr>
<td><strong>Intraoperative Analgesics Used</strong></td>
<td>10 mL (133 mg) of EXPAREL (unexpanded)</td>
</tr>
<tr>
<td><strong>Dose of EXPAREL and Total Volume Used</strong></td>
<td><img src="image" alt="EXPAREL (133 mg)" /></td>
</tr>
</tbody>
</table>

*EXPAREL is not indicated for use in nerve block.

The recommended dose of EXPAREL is based on the size of the surgical site, the volume required to cover the area, and individual patient factors that may impact the safety of an amide local anesthetic. The maximum dose of EXPAREL should not exceed 266 mg.

EXPAREL can be administered undiluted (20 mL) or diluted to increase volume up to a total of 300 mL (final concentration of 0.89 mg/mL [ie, 1:14 dilution by volume]) with normal (0.9%) saline or lactated Ringer’s solution.

Bupivacaine HCl may be administered immediately before EXPAREL or admixed in the same syringe, as long as the ratio of the milligram dose of bupivacaine HCl to EXPAREL does not exceed 1.2. Admixing may impact the pharmacokinetic and/or physiochemical properties of EXPAREL, and this effect is concentration dependent. The toxic effects of these drugs are additive and their administration should be used with caution, including monitoring for neurological and cardiovascular effects related to toxicity. Other than with bupivacaine HCl, EXPAREL should not be admixed with other drugs prior to administration.

Please see Important Safety Information on the last page and refer to the accompanying full Prescribing Information for complete Dosage and Administration information before using EXPAREL.
**INFORMATION PRESENTATION**

**ASSESS THE SIZE OF THE SURGICAL SITE AND DEPTH OF TISSUE, THEN PREPARED INJECTION MATERIALS ACCORDINGLY**

In this procedure, the panoramic radiograph showed the soft tissue–impacted maxillary third molars and partial bony–impacted mandibular third molars. Dr Lieblich assessed the surgical sites and determined he would need the following to provide analgesic coverage:

- 1.7 mL of 2% lidocaine with 1:100,000 epinephrine for infiltration into buccal aspect and 0.2 mL into palatal aspect of each upper third molar
- 1.7 mL of 2% lidocaine with 1:100,000 epinephrine for each lower inferior alveolar nerve block and lingual nerve block in the mandible
- 1.5 mL of 0.5% bupivacaine HCl with 1:100,000 epinephrine for each lower inferior alveolar nerve block
- 0.3 mL of 0.5% bupivacaine HCl with 1:100,000 epinephrine for each long buccal nerve block

Dr Lieblich also determined that he would need a total volume of approximately 10 mL of EXPAREL (unexpanded).

**INFILTRATION AND NERVE BLOCK WITH NON-EXPAREL ANALGESICS**

**UPPER MOLARS**

- **Step #1:** Buccal and palatal infiltration of teeth #1 and #16 (lidocaine with epinephrine)

**LOWER MOLARS**

- **Step #2:** Inferior alveolar and lingual nerve block for teeth #17 and #32 (lidocaine with epinephrine)
- **Step #3:** Inferior alveolar and long buccal nerve block (bupivacaine HCl with epinephrine)

**INFILTRATION WITH EXPAREL**

- **Step #4:** Lateral aspect of mandible for teeth #17 and #32
- **Step #5:** Buccal aspect of teeth #1 and #16

**Dr Lieblich used bupivacaine HCl with epinephrine for the long buccal nerve block because non–bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Formulations of bupivacaine other than EXPAREL should not be administered within 96 hours following administration of EXPAREL.**

**INFILTRATED INTO THE FOLLOWING AREAS USING A 22-GAUGE NEEDLE**

Dr Lieblich planned to infiltrate as follows:

- For teeth #1 and #16, Dr Lieblich infiltrated 1.7 mL of 2% lidocaine with 1:100,000 epinephrine into the buccal aspect and 0.2 mL into the palatal aspect.
- For teeth #17 and #32, Dr Lieblich administered 1.7 mL of 2% lidocaine with 1:100,000 epinephrine into the inferior alveolar nerve and 1.7 mL into the lingual nerve in the mandible, on each side, to create nerve blocks.
- Dr Lieblich infiltrated 1.5 mL of 0.5% bupivacaine HCl with 1:100,000 epinephrine into the inferior alveolar nerve and 0.3 mL into the long buccal nerve, on each side, to create nerve blocks.
- After primary closure, Dr Lieblich infiltrated 4 mL of EXPAREL along the lateral aspect of the mandible, on each side, as 4 separate 1-mL injections, for a total of 8 mL. For each injection, the needle was inserted into the base, aspirated, and then 1 mL of EXPAREL was injected as the needle was withdrawn, creating a column effect—ensuring maximum analgesic coverage.
- Dr Lieblich then infiltrated 1 mL of EXPAREL into the buccal aspect of the upper third molars, on each side, for a total of 2 mL.

Please see Important Safety Information on the last page and refer to the accompanying full Prescribing Information for complete Dosage and Administration information before using EXPAREL.
**Important Safety Information**

EXPAREL is contraindicated in obstetrical paracervical block anesthesia.

In clinical trials, the most common adverse reactions (incidence $\geq 10\%$) following EXPAREL administration were nausea, constipation, and vomiting.

EXPAREL is not recommended to be used in the following patient population: patients $<18$ years old and/or pregnant patients.

Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations.

**Warnings and Precautions Specific to EXPAREL**

EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks, or intravascular or intra-articular use.

Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Formulations of bupivacaine other than EXPAREL should not be administered within 96 hours following administration of EXPAREL.

**Warnings and Precautions for Bupivacaine-Containing Products**

**Central Nervous System (CNS) Reactions:** There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesias. CNS reactions are characterized by excitation and/or depression.

**Cardiovascular System Reactions:** Toxic blood concentrations depress cardiac conductivity and excitability which may lead to dysrhythmias sometimes leading to death.

**Allergic Reactions:** Allergic-type reactions (eg, anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients.

**Chondrolysis:** There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use.

**Disclosure:** Dr Lieblich is a paid consultant for Pacira Pharmaceuticals, Inc.